The Traumatic Brain Injury market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Traumatic Brain Injury: An Overview
According to the American Association of Neurological Surgeons (AANS), Traumatic Brain Injury (TBI) is defined as a blow to the head or a penetrating head injury that disrupts the normal functioning of the brain. It can result when the head suddenly and violently hits an object or when an object pierces the skull and enters brain tissue.
In Traumatic Brain Injury patients, Neurologic Damage is divided into two types: Primary Damage and Secondary Damage. Primary damage includes Coup-Contrecoup Injury, Skull Fracture, Contusion/Bruise and Nerve Damage.
While secondary damage that occurs over time after the actual brain injury; may include infection, hypoxia (oxygen deprivation), edema (brain swelling), elevated intracranial pressure, infarction (death of brain tissue which results in loss of blood supply to that region of the brain), and hematoma (focal area of bleeding in the skull due to tearing of blood vessels).
Traumatic Brain Injury Market Key Facts
Approximately, 2.8 million people sustain Traumatic Brain Injury annually in the United States and every day 153 people in the United States die from injuries that include Traumatic Brain Injury as per Brain line organization.
As per the Centers for Disease Control and Prevention (CDC) report, in the last decade, rates of Traumatic Brain Injury-related deaths in men decreased from 27.8 to 25.4 per 100,000 and rates in women decreased from 9.6 to 9.0 per 100,000. Men had more than twice the rate of TBI-related deaths as compared to women.
Centres for Disease Control and Prevention reported that over the span of six years (2007–2013) Traumatic Brain Injury-related ED visits have increased by 47%, hospitalization rates decreased by 2.5% and death rates decreased by 5%.
As per the American Association of Neurological Surgeons, “about 1.7 million cases of Traumatic Brain Injury occur in the U.S. every year. Approximately 5.3 million people live with a disability caused by TBI in the U.S. alone.”
Owing to the launch of upcoming therapies the Traumatic Brain Injury market size is expected to increase during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Traumatic Brain Injury market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Traumatic Brain Injury market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Traumatic Brain Injury Epidemiology
The epidemiology section covers insights into the historical and current Traumatic Brain Injury patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Traumatic Brain Injury Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Traumatic Brain Injury market or expected to get launched in the market during the study period. The analysis covers Traumatic Brain Injury market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Traumatic Brain Injury Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/traumatic-brain-injury-market
Traumatic Brain Injury Therapeutics Analysis
Some of the key Companies in the Traumatic Brain Injury Market include:
NeuroVive Pharmaceutical AB
And many others.
Traumatic Brain Injury therapies covered in the report include:
And many others.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/traumatic-brain-injury-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Traumatic Brain Injury Competitive Intelligence Analysis
4. Traumatic Brain Injury Market Overview at a Glance
5. Traumatic Brain Injury Disease Background and Overview
6. Traumatic Brain Injury Patient Journey
7. Traumatic Brain Injury Epidemiology and Patient Population
8. Traumatic Brain Injury Treatment Algorithm, Current Treatment, and Medical Practices
9. Traumatic Brain Injury Unmet Needs
10. Key Endpoints of Traumatic Brain Injury Treatment
11. Traumatic Brain Injury Marketed Products
12. Traumatic Brain Injury Emerging Therapies
13. Traumatic Brain Injury Seven Major Market Analysis
14. Attribute Analysis
15. Traumatic Brain Injury Market Outlook (7 major markets)
16. Traumatic Brain Injury Access and Reimbursement Overview
17. KOL Views on the Traumatic Brain Injury Market.
18. Traumatic Brain Injury Market Drivers
19. Traumatic Brain Injury Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/traumatic-brain-injury-market
Other Latest Reports By DelveInsight
The “Injectable Drug Delivery Devices Market” is expected to reach USD 33.37 billion by 2026. Some of the key MedTech companies such Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others, are actively working in the Injectable Drug Delivery Devices Market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States